ChroMedX Engages Polygenesis Corporation for Completion of HemoPalm(TM) Alpha
ChroMedX Corp, a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to announce the engagement of technology development and prototyping firm Polygenesis Corporation to continue the development of the HemoPalm biosensor array, a fundamental component of the HemoPalm system.
View full press release